Vicente Anido, Jr. nominated for election to Nicox's Board of Directors
SOPHIA ANTIPOLIS CEDEX, FRANCE -- (Marketwired) -- 04/26/13 -- Nicox
S.A. (NYSE Euronext Paris: COX) today announced that the Company's
Board of Directors has nominated Vicente Anido, Jr., PhD., to be
elected to the Board.
Dr. Anido is a highly respected and
experienced leader in the ophthalmology
sector. He most recently
served as President and Chief Executive Officer of
Pharmaceuticals prior to its acquisition by Bausch + Lomb. The
election of Dr.
Anido to Nicox's Board will be voted on at the
Company's 2013 Ordinary Shareholder Meeting, which will be convened
for June 6, 2013.
"The Board is pleased to propose Vince Anido as a Board member of
has a wealth of experience in the management of
pharmaceutical companies, particularly in the ophthalmic area. We
believe he would be a significant addition to the existing strength
and combined experience of the Nicox Board as we work towards
building an international ophthalmology business," said
Garufi, Chief Executive Officer of Nicox.
About Vicente Anido, Jr.
From 2001 to 2012, Dr. Anido was President, Chief Executive Officer
and a Director of ISTA Pharmaceuticals, a US-based ophthalmic
Prior to this, he was general partner of
Windamere Venture Partners, served as
President and CEO of CombiChem,
Inc., a biotechnology company, and was President
of the Americas
Region of Allergan, a specialty pharmaceutical company focusing
ophthalmology, dermatology and neuromuscular indications. Dr. Anido
currently serves on the Board of Directors of QLT Inc. and
Inc., two NASDAQ-listed pharmaceutical companies, and was
recently named Chairman of the Board of Directors of Aerie
Pharmaceuticals, a US private ophthalmic company.
Dr. Anido received a B.S. in Pharmacy, an M.S. in Pharmacy
West Virginia University and a Ph.D. in Pharmacy
Administration from the University of Missouri.
Information on the 2013 Ordinary Shareholder Meeting is available on
the Nicox internet website:
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new
international player in the ophthalmic market by
building a diversified
portfolio of innovative therapies and
diagnostic tools. With a heritage of scientific, business
development and commercial expertise, the Nicox team is focused on
developing and marketing novel pharmaceuticals and diagnostic
that can help people to enhance their sight. In the United
States, Nicox markets
AdenoPlus(TM), a test for the differential
diagnosis of acute conjunctivitis in- licensed from RPS(R).
The Company's pipeline includes latanoprostene bunod, a novel
based on Nicox's proprietary nitric oxide
(NO)-donating R&D platform, developed
in collaboration with Bausch +
Lomb for the potential treatment of glaucoma and ocular hypertension.
Further NO-donating compounds are under development in
non-ophthalmic indications, notably through partners, including
Merck (known as MSD outside the United States and Canada) and Ferrer.
Nicox S.A. is headquartered in France and is listed on
(Compartment B: Small Caps). For more information
please visit www.nicox.com.
This press release contains certain forward-looking statements.
Company believes its expectations are based on reasonable
forward-looking statements are subject to numerous
risks and uncertainties, which could cause actual results to differ
materially from those anticipated in the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's
business are presented in the 4th chapter of the << Document de
reference, rapport financier annuel et rapport de gestion 2012 >>
filed with the French Autorite des Marches Financiers (AMF) on March
22, 2013 and available on Nicox's website (www.nicox.com) and on the
AMF's website (www.amf-france.org).
Vicente Anido, Jr. nominated for
election to Nicox's Board of Director:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE
Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00
D +44 (0)20 7269 7205
M +44 (0) 7515 597 858
D +44 (0)20 3077 0458
M +44 (0) 7843 080947
2405 route des Dolines
06560 Valbonne, France
T: +33 (0)4 97 24 53 00
F: +33 (0)4 97 24 53 99
Press spacebar to pause and continue. Press esc to stop.